MGC Pharmaceuticals’ “historic” March quarter highlighted by LSE listing and record sales
MGC Pharma became the first medicinal cannabis company to list on the London Stock Exchange, amid record sales of its phytomedicines.
Company
Argent BioPharma Ltd
ASX:RGT
Argent BioPharma Ltd is a European-based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant-inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions. The company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high-quality plant-inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia. Argent BioPharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
157 stories · page 8 of 8
Proactive news headlines: MGC Pharmaceuticals, NFT Investments, Trident Royalties, Belvoir Group...
A glance at some of the day's headlines from the Proactive Investors newswire
MGC Pharmaceuticals to acquire worldwide clinical and medical research company MediCaNL
The acquisition leverages the medical research expertise in-house which will reduce preclinical lead times, provide the ability to better define clinical trial protocols and build stronger relationships with regulators moving forward.
Argent Biopharma to accelerate clinical pipeline development
MGC Pharma, which has three investigational medical products in three clinical trials, has reported a record quarter of sales and revenue.
MGC Pharmaceuticals sees strong market outlook as global phytocannabinoid market gains traction
The European-based, vertically integrated biopharma, has three investigational medical products in three clinical trials.
MGC Pharmaceuticals appoints new joint company secretary in Nadine Barry
Narelle Warren has resigned from the role and the board expresses its thanks for her contribution which included the successful dual listing on the London Stock Exchange in February.
MGC Pharma delivers first major ArtemiC Rescue order to Swiss PharmaCan, achieves record quarter for sales revenues
It has delivered a record quarter of sales revenues from its proprietary phytomedicine product line, with about $880,000 of revenue generated for the March 2021 quarter.
MGC Pharmaceuticals gains 7% on approval for Phase III trial of CimetrA
The company said the trial will evaluate the efficacy and safety of CimetrA in the treatment of moderate hospitalised patients diagnosed with COVID-19
MGC Pharmaceuticals shares higher after director dealing
Last month the company secured its first deal to supply its food supplement product, ArtemiC
MGC Pharmaceuticals director shows support for company’s ArtemiC product with on-market purchase
The company’s distributor Swiss PharmaCan recently increased its initial order volume for ArtemiC Rescue, an anti-inflammatory product targeting COVID-19, by 85%.
MGC Pharmaceuticals says distributor has increased initial order for COVID-19 supplement 85%
"This further agreement will provide more people access to the natural therapeutic benefits of the supplement,” said managing director Roby Zomer
MGC Pharmaceuticals reports strong financial position as it drives medical cannabis growth
Milestones during the period included an acquisition, first product shipments, expansion of manufacturing facilities and continued clinical progress
Cannabis company MGC Pharmaceuticals soars on food supplement product deal
The company is also carrying out clinical trials of ArtemiC into the treatment of COVID-19
MGC Pharmaceuticals signs supply and distribution agreement with Swiss PharmaCan for ArtemiC™ Rescue
The company has signed a minimum three-year exclusive worldwide supply and distribution agreement with Swiss PharmaCan for the distribution of ArtemiC™ Rescue as a food supplement.
Roll up roll up: Cannabis companies queue up to join London's budding subsector
London's cannabis sector is finally budding two decades after GW Pharma blazed a trail, with debutants MGC Pharmaceuticals and Kanabo Group both warmly welcomed after listing this month
MGC Pharmaceutical to start new In-vitro cannabinoid study on glioblastoma brain cancer treatment using nano-delivery platform
The preliminary results of its proprietary cannabinoid treatment of glioblastoma have recently completed an independent peer review and been published in the MDPI (Multidisciplinary Digital Publishing Institute) Medical Journal.
Cannabis stocks sent higher in new Reddit investor rally
Like with GameStop, some cannabis stocks have been targets of Wall Street short sellers